FilingsTodayAlnylam Pharmaceuticals
At a glance
Alnylam Pharmaceuticals reported 2025 revenue of $3.71B, up 65.2% from $2.25B in 2024. Over 4 years since 2021 ($844.3M), that is growth of about 44.8% a year. Operating margin was 13.5%, up from -83.9% in 2021. 2025 was the highest revenue year in this period. The company posted a loss in 2021, 2022, 2023 and 2024.
In the last 12 months 8 insiders reported 0 open-market purchases and 24 sales ($42.7M). 11 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $11.6M by Chief Executive Officer Yvonne Greenstreet on Nov 14, 2025.
Alnylam Pharmaceuticals filed 9 current reports (Form 8-K) in the last 12 months, most often for results of operations (5), officer or director change (3), shareholder vote results (1) and other events (1). The latest officer or director change was reported on May 27, 2026.
2 of the 20 investors tracked here held Alnylam Pharmaceuticals at the last quarter end, worth $89.7M combined. It is the largest weight for Bridgewater Associates (0.1% of its portfolio), followed by National Pension Service (Korea) (0%). Added: National Pension Service (Korea). Reduced: Bridgewater Associates.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | -$852.8M | -$1.13B | -$440.2M | -$278.2M | $313.7M |
| Diluted EPS | $-7.20 | $-9.30 | $-3.52 | $-2.18 | $2.33 |
Fiscal year ends Dec 31
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined